Moreover, we clarified the role of PLCG2 in remodeling the immunosuppressive microenvironment and explored the translational value of targeting PLCG2 to potentiate the efficacy of ICB therapy and improve the prognosis for CRC in preclinical animal models. Here, PLCG2 is linked to colorectal carcinoma.